Olema Pharmaceuticals Stock (NASDAQ:OLMA)
Previous Close
$11.62
52W Range
$8.51 - $17.79
50D Avg
$12.01
200D Avg
$12.14
Market Cap
$679.18M
Avg Vol (3M)
$479.69K
Beta
2.03
Div Yield
-
OLMA Company Profile
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
SANA | Sana Biotechnology, Inc. |
CGEM | Cullinan Oncology, Inc. |
ZNTL | Zentalis Pharmaceuticals, Inc. |
CNTA | Centessa Pharmaceuticals plc |
LRMR | Larimar Therapeutics, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
ERAS | Erasca, Inc. |
OBIO | Orchestra BioMed Holdings, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
IRON | Disc Medicine, Inc. |
ANTX | AN2 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
PEPG | PepGen Inc. |
MOLN | Molecular Partners AG |
LIFE | aTyr Pharma, Inc. |
NVCT | Nuvectis Pharma, Inc. |